CD40-gp39 interactions play a critical role during allograft rejection: Suppression of allograft rejection by blockade of the CD40-gp39 pathway

Transplantation

Volumn 61, Issue 1, 1996, Pages 4-9

  Larsen, Christian P ^a,b   Alexander, Diane Z ^a   Hollenbaugh, Diane ^c   Elwood, Eric T ^a   Ritchie, Shannon C ^a   Aruffo, Alejandro ^c   Hendrix, Rose ^a   Pearson, Thomas C ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY HOSPITAL   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; CELL SURFACE PROTEIN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MR1; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; GRAFT REJECTION; HEART TRANSPLANTATION; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIGENS, CD40; BASE SEQUENCE; CD40 LIGAND; GRAFT REJECTION; HEART TRANSPLANTATION; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 0030046808     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199601150-00002     Document Type: Article

References (32)

1. Dallman MJ, Mason DW, Webb M. The roles of host and donor cells in the rejection of skin allografts by T cell-deprived rats injected with syngeneic T cells. Eur J Immunol 1982; 12: 511-518.
2. Bolton EM, Gracie JA, Briggs JD, Kampinga J, Bradley JA. Cellular requirements for renal allograft rejection in the athymic nude rat. J Exp Med 1989; 169: 1931-1946.
3. June CH, Ledbetter JA, Linsley PS, Thompson CB. Role of the CD28 receptor in T-cell activation. Immunol Today 1990; 11(6): 211-216.
4. Jenkins MK, Taylor PS, Norton SD, Urdahl KB. CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. J Immunol 1991; 147(8): 2461-2466.
5. Hollenbaugh D, Grosmaire LS, Kullas CD, et al. The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity. Embo J 1992; 11(12): 4313-4321.
6. Armitage RJ, Fanslow WC, Strockbine L, et al. Molecular and biological characterization of a murine ligand for CD40. Nature 1992; 357(6373): 80-82.
7. Caux C, Massacrier C, Vanbervliet B, et al. Activation of human dendritic cells through CD40 cross-linking. J Exp Med 1994; 180(4): 1263-1272.
8. Pinchuk L, Polacino P, Agy M, Klaus S, Clark E. The role of CD40 and CD80 accessory cell molecules in dendritic cell-dependent HIV-1 infection. Immunity 1994; 1: 317-325.
9. Ranheim EA, Kipps TJ. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med 1993; 177(4): 925-935.
10. Noelle R, Roy M, Shepherd D, Stamenkovic I, Ledbetter J, Aruffo A. A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc Natl Acad Sci U S A 1992; 89: 6550-6554.
11. Lane P, Brocker T, Hubele S, Padovan E, Lanzavecchia A, Mc-Connell F. Soluble CD40 ligand can replace the normal T cell-derived CD40 ligand signal to B cells in T cell-dependent activation. J Exp Med 1993; 177(4): 1209-1213.
12. Alderson M, Armitage R, Tough T, Strockbine L, Fanslow W, Spriggs M. CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40. J Exp Med 1993; 178: 669-674.
13. Tian L, Noelle R, Lawrence D. Activated T cell enhance nitric oxide production by murine splenic macrophages through gp39 and LFA-1. Eur J Immunol 1995; 25: 306-309.
14. Durie FH, Fava RA, Foy TM, Aruffo A, Ledbetter JA, Noelle RJ. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science 1993; 261(5126): 1328-1330.
15. Foy TM, Shepherd DM, Durie FH, Aruffo A, Ledbetter JA, Noelle RJ. In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. II. Prolonged suppression of the humoral immune response by an antibody to the ligand for CD40, gp39. J Exp Med 1993; 178(5): 1567-1575.
16. Van den Eertwegh AJM, Noelle RJ, Roy M, et al. In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. I. In vivo expression of CD40 ligand, cytokines, and antibody production delineates sites of cognate T-B cell interactions. J Exp Med 1993; 178(5): 1555-1565.
17. Renshaw BR, Fanslow WC, Armitage RJ, et al. Humoral immune responses in CD40 ligand-deficient mice. J Exp Med 1994; 180(5): 1889-1900.
18. Mohan C, Shi Y, Laman JD, Datta SK. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol 1995; 154(3): 1470-1480.
19. Corry RJ, Winn HJ, Russell PS. Primarily vascularized allografts of hearts in mice: the role of H-2D, H-2K, and non H-2 antigens in rejection. Transplantation 1973; 16(4): 343-350.
20. Dallman MJ, Larsen CP, Morris PJ. Cytokine gene transcription in vascularized organ grafts: analysis using semi-quantitative polymerase chain reaction. J Exp Med 1991; 174: 493-496.
21. Kawabe T., Naka T, Yoshida K, et al. The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. Immunity 1994; 1: 167-178.
22. Aruffo A., Farrington M, Hollenbaugh D, et al. The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell 1993; 72(2): 291-300.
23. + T lymphocytes. J Immunol 1994; 152(4): 1523-1531.
24. Worrall NK, Lazenby WD, Misko TP, et al. Modulation of in vivo alloreactivity by inhibition of inducible nitric oxide synthase. J Exp Med 1995; 181(1): 63-70.
25. Ramsdell F, Fowlkes BJ. Maintenance of in vivo tolerance by persistence of antigen. Science 1992; 257(5073): 1130-1134.
26. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12: 991-1045.
27. Ju ST, Panka DJ, Cui H. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 1995; 373: 444-448.
28. Torres R, Clark E. Differential increase of an alternatively polyadenylated mRNA species of murine CD40 upon B lymphocyte activation. J Immunol 1992; 148: 620-626.
29. 2-line effector cells in peripheral tolerance. Transplantation 1992; 53: 1281-1294.
30. Stenger S, Thuring H, Rollinghoff M, Bogdan C. Tissue expression of inducible nitric oxide synthase is closely associated with resistance to Leishmania major. J Exp Med 1994; 180(3): 783-793.
31. Freeman GJ, Gray GS, Gimmi CD, et al. Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7. J Exp Med 1991; 174: 625-631.
32. Freeman G, Borriello F, Hodes R, et al. Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and Interleukin 2 production. J Exp Med 1993; 178: 2185-2192.